John C. Pesko

849 total citations
21 papers, 309 citations indexed

About

John C. Pesko is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, John C. Pesko has authored 21 papers receiving a total of 309 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 9 papers in Pathology and Forensic Medicine and 7 papers in Hematology. Recurrent topics in John C. Pesko's work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (7 papers) and Multiple Myeloma Research and Treatments (6 papers). John C. Pesko is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (7 papers) and Multiple Myeloma Research and Treatments (6 papers). John C. Pesko collaborates with scholars based in United States, Australia and Switzerland. John C. Pesko's co-authors include Arvind Caprihan, Erik B. Erhardt, Gary A. Rosenberg, Ahmed Hamed Salem, Kieron Dunleavy, John P. Leonard, Jasmine Zain, Sven de Vos, Rod Humerickhouse and Jonathan W. Friedberg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

John C. Pesko

21 papers receiving 305 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John C. Pesko United States 9 101 97 77 77 72 21 309
Sana Syed United States 7 63 0.6× 99 1.0× 172 2.2× 55 0.7× 59 0.8× 21 340
Μαρία Καραμίτα Greece 7 78 0.8× 48 0.5× 62 0.8× 15 0.2× 30 0.4× 10 288
Fadi Saadeh Lebanon 9 177 1.8× 168 1.7× 14 0.2× 24 0.3× 107 1.5× 13 475
Mariangela Mastrapasqua Italy 11 154 1.5× 120 1.2× 95 1.2× 11 0.1× 17 0.2× 19 432
Casey MM Pfluger Australia 9 55 0.5× 113 1.2× 106 1.4× 9 0.1× 69 1.0× 11 428
Azza Ismail United Kingdom 10 65 0.6× 60 0.6× 57 0.7× 11 0.1× 14 0.2× 16 268
P. Cervera France 2 44 0.4× 36 0.4× 85 1.1× 14 0.2× 64 0.9× 2 302
Sonja Ortler Germany 10 46 0.5× 24 0.2× 96 1.2× 20 0.3× 80 1.1× 17 399
Isabelle Paré Canada 9 91 0.9× 25 0.3× 19 0.2× 31 0.4× 31 0.4× 18 364
Aleš Dudešek Germany 11 137 1.4× 29 0.3× 61 0.8× 17 0.2× 17 0.2× 17 481

Countries citing papers authored by John C. Pesko

Since Specialization
Citations

This map shows the geographic impact of John C. Pesko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John C. Pesko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John C. Pesko more than expected).

Fields of papers citing papers by John C. Pesko

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John C. Pesko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John C. Pesko. The network helps show where John C. Pesko may publish in the future.

Co-authorship network of co-authors of John C. Pesko

This figure shows the co-authorship network connecting the top 25 collaborators of John C. Pesko. A scholar is included among the top collaborators of John C. Pesko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John C. Pesko. John C. Pesko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Davids, Matthew S., Andrew W. Roberts, Vaishalee P. Kenkre, et al.. (2021). Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study. Clinical Cancer Research. 27(17). 4690–4695. 48 indexed citations
2.
Cochrane, Tara, Alicia Enrico, David Gómez‐Almaguer, et al.. (2021). Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial. Leukemia & lymphoma. 63(2). 304–314. 6 indexed citations
3.
Ciesielski, Kristina T., et al.. (2021). Posterior brain sensorimotor recruitment for inhibition of delayed responses in children. Experimental Brain Research. 239(11). 3221–3242. 1 indexed citations
4.
Davids, Matthew S., Kirsten Fischer, Sandra Robrecht, et al.. (2021). ReVenG: A Phase 2 Study of Venetoclax Plus Obinutuzumab Retreatment in Patients with Relapsed Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 2634–2634. 8 indexed citations
5.
Zhang, Guoyi, Ronald Christensen, & John C. Pesko. (2021). Parametric boostrap and objective Bayesian testing for heteroscedastic one-way ANOVA. Statistics & Probability Letters. 174. 109095–109095. 8 indexed citations
6.
Flinn, Ian W., David Andorsky, Jason M. Melear, et al.. (2021). Debulking before Initiation of Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Results from a Phase 3b Study. Blood. 138(Supplement 1). 3725–3725. 1 indexed citations
7.
Ma, Shuo, John F. Seymour, Danielle M. Brander, et al.. (2021). Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy. Blood. 138(10). 836–846. 24 indexed citations
8.
Rubnitz, Jeffrey E., Thomas Alexander, Theodore W. Laetsch, et al.. (2020). Venetoclax and Navitoclax in Pediatric Patients with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. Blood. 136(Supplement 1). 12–13. 1 indexed citations
9.
Vos, Sven de, John P. Leonard, Jonathan W. Friedberg, et al.. (2020). Safety and efficacy of navitoclax, a BCL-2 and BCL-X L inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study. Leukemia & lymphoma. 62(4). 810–818. 55 indexed citations
10.
Flinn, Ian W., David Andorsky, Jason M. Melear, et al.. (2020). Debulking Regimens Prior to Initiating Venetoclax Therapy in Untreated Patients with Chronic Lymphocytic Leukemia: Interim Results from a Phase 3b Study. Blood. 136(Supplement 1). 4–5. 2 indexed citations
11.
Kaufman, Jonathan L., Cristina Gasparetto, Fredrik Schjesvold, et al.. (2019). Phase I/II Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Dexamethasone As Targeted Therapy for Patients with t(11;14) Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 926–926. 16 indexed citations
12.
Costa, Luciano J., E. Stadtmauer, Faith E. Davies, et al.. (2019). PS1375 UPDATED SAFETY AND EFFICACY FROM A PHASE 2 STUDY OF VENETOCLAX PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere. 3(S1). 629–629. 2 indexed citations
13.
Bahlis, Nizar J., Rachid Baz, Simon J. Harrison, et al.. (2019). First Analysis from a Phase 1/2 Study of Venetoclax in Combination with Daratumumab and Dexamethasone, +/- Bortezomib, in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 925–925. 9 indexed citations
14.
Raz, Limor, Kiran Bhaskar, John Weaver, et al.. (2018). Hypoxia promotes tau hyperphosphorylation with associated neuropathology in vascular dysfunction. Neurobiology of Disease. 126. 124–136. 59 indexed citations
15.
Raz, Limor, Yi Yang, Jeffrey Thompson, et al.. (2018). MMP-9 inhibitors impair learning in spontaneously hypertensive rats. PLoS ONE. 13(12). e0208357–e0208357. 5 indexed citations
16.
Erhardt, Erik B., John C. Pesko, Jillian Prestopnik, et al.. (2018). Biomarkers identify the Binswanger type of vascular cognitive impairment. Journal of Cerebral Blood Flow & Metabolism. 39(8). 1602–1612. 22 indexed citations
17.
Costa, Luciano J., Edward A. Stadtmauer, Gareth J. Morgan, et al.. (2018). Phase 2 Study of Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 132(Supplement 1). 303–303. 16 indexed citations
18.
Bueno, Orlando F., Michelle Jacobson, John C. Pesko, et al.. (2018). A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma.. Journal of Clinical Oncology. 36(15_suppl). TPS8061–TPS8061. 1 indexed citations
19.
Costa, Luciano J., Edward A. Stadtmauer, Gareth J. Morgan, et al.. (2018). Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.. Journal of Clinical Oncology. 36(15_suppl). 8004–8004. 17 indexed citations
20.
Pesko, John C., et al.. (2015). Improving Depth of Thinking in Online Discussion Boards.. The Quarterly Review of Distance Education. 16(3). 45–66. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sana Syed Breakdown of academic impact, for papers by Μαρία Καραμίτα Breakdown of academic impact, for papers by Fadi Saadeh Breakdown of academic impact, for papers by Mariangela Mastrapasqua Breakdown of academic impact, for papers by Casey MM Pfluger Breakdown of academic impact, for papers by Azza Ismail Breakdown of academic impact, for papers by P. Cervera Breakdown of academic impact, for papers by Sonja Ortler Breakdown of academic impact, for papers by Isabelle Paré Breakdown of academic impact, for papers by Aleš Dudešek
Rankless by CCL
2026